SHANGHAI, China, Dec. 9 /Xinhua-PRNewswire/ -- WuXi PharmaTech, the leading provider of chemistry R&D and manufacturing services, announces today that it is ranked the 83rd in Deloitte Technology Fast 500 Asian Pacific 2005 annual competition. The program is a ranking of the 500 leading technology companies across the Asia Pacific region based on percentage revenue growth over five years. From 2001 to 2005, WuXi PharmaTech grew more than 100 times.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
This is the second consecutive award WuXi PharmaTech has received from Deloitte. The company was the 9th winner of Deloitte Technology Fast 500 Asia Pacific 2004 last year and most recently was ranked the 22rd in Deloitte Technology Fast 50 China.
''It is a good achievement and we are very proud and pleased to win the award again,’' WuXi PharmaTech’s Chairman & CEO Dr. Ge Li said when heard the news. ''WuXi PharmaTech has come of age in 2005 as we set our course to becoming a great service company. The company and the management team have matured and become more sophisticated in many ways. We will continue to focus on building a stronger service platform for our partners.’'
The winning companies come from a variety of technology businesses and industry sectors from across Asian Pacific. It is calculated that 16.4% of the 500 winners are from China including Hong Kong, and 4% from the Bio-Pharmaceutical sector.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other’s acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names ''Deloitte’’, ''Deloitte & Touche’’, ''Deloitte Touche Tohmatsu’’, or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein.
About WuXi PharmaTech
Shanghai-based WuXi PharmaTech Co., Ltd. offers global pharmaceutical/bio- pharmaceutical companies diverse outsourcing services in combinatorial, medicinal, synthetic chemistry and manufacturing. Importantly, it also allows them to take full advantage of the lower research costs in China. WuXi PharmaTech’s rapidly expanding line of services ranges from early stage discovery chemistry through lead optimization chemistry, all the way to process research & development and bulk manufacture of active pharmaceutical ingredients. With the addition of a new GMP plant at Jinshan in Shanghai, WuXi PharmaTech has further increased its bulk production capacity to meet rapidly growing customer demand. WuXi PharmaTech’s strong capabilities and impressive track record enable the company to provide a broad spectrum of integrated development services from milligram to metric ton scaled active pharmaceutical ingredients, intermediates and raw materials. Currently, WuXi PharmaTech’s client list includes over 60 leading drug discovery companies covering a majority of the world’s largest pharmaceutical companies.
For more information, please contact: David Yin, PR Department, WuXi PharmaTech Co., Ltd. Tel: +86-21-5046-4003 Fax: +86-21-5046-1000 Email: Yin_Xiaojun@pharmatechs.com Web: http://www.pharmatechs.comhttp://www.pharmatechs-us.comhttp://www.pharmatechs.com.cn
Photo: NewsCom:http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGOPRN Photo Desk, +1-888-776-6555 or +1-212-782-2840Wuxi PharmaTech Co., Ltd.
CONTACT: David Yin, PR Department of WuXi PharmaTech Co., Ltd.,+86-21-5046-4003 or fax +86-21-5046-1000, or Yin_Xiaojun@pharmatechs.com
